Andrea Clay

Andrea Clay supports the National Institute on Drug Abuse (NIDA) in advancing scientific research through strategic procurement of specialized scientific and technical services. She manages acquisitions aligned with NIDA’s mission to fund cutting-edge research on substance use disorders, focusing on contracts that enable neurobiological, behavioral, and clinical translation studies. Her portfolio primarily includes research services, analytical laboratory instrumentation, and medical testing solutions, ensuring that grantees and contractors have access to high-precision tools and expert analytical capabilities essential for drug abuse research. She plays a critical role in aligning procurement decisions with federal research priorities and ensuring compliance with NIH and HHS acquisition policies. Clay maintains strong, long-term relationships with leading academic medical institutions including McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships reflect a preference for high-caliber research organizations capable of delivering complex, multi-site studies and advanced laboratory analyses. Her contracting approach emphasizes scientific rigor, reproducibility, and compliance with NIH grant compliance standards, often supporting investigator-initiated research through performance-based service contracts and cooperative agreements. Her procurement patterns show a strong preference for open competition, with 85.7% of awards issued without set-asides, indicating a focus on technical merit over socioeconomic categorization. However, she consistently allocates 14.3% of awards to total small business set-asides under FAR 19.5, demonstrating targeted support for qualified small businesses capable of delivering specialized research and analytical services. Clay’s primary NAICS focus areas include analytical laboratory instrument manufacturing (334516), medical laboratories (621511), and biotechnology R&D (541714), reflecting her specialization in procuring high-end instrumentation, clinical testing infrastructure, and neuroscientific research services. She frequently acquires precision equipment for drug metabolism analysis, behavioral monitoring systems, and biomarker detection platforms, underscoring her deep technical expertise in supporting the scientific infrastructure of addiction research.